Kurs & Likviditet
|2023-05-17||Extra Bolagsstämma 2023|
|2022-11-24||Ordinarie utdelning SELECT B 0.00 SEK|
|2021-11-25||Ordinarie utdelning SELECT B 0.00 SEK|
|2020-11-26||Ordinarie utdelning SELECT B 0.00 SEK|
|2019-11-21||Ordinarie utdelning SELECT B 0.00 SEK|
|Industri||Läkemedel & Handel|
Shareholders, who at the time of this press release in total represent more than 50 percent of all votes, have amended their previous proposal to the upcoming Annual General meeting on November 23[rd] concerning the election of chairman of the meeting, board of directors, auditor, and remuneration to the board of directors and auditor (items 2 and 10-15) to the following proposal.
Jan Zetterberg, who is the company's lawyer, is proposed as chairman of the meeting. Furthermore, five board members are proposed without a deputy. Fee for the chairman of the board is not paid, a fixed fee of SEK 75,000 is paid for other external board members, auditor's fee is according to approved bill, re-election of Catharina Svanborg (chair), Helena Lomberg, Carl-Johan Wachtmeister and Gabriela Godaly and election of Magnus Nylén, as a new member of the Board. Furthermore, it is proposed to re-elect the Auditors Group in Malmö AB as auditor until the next annual general meeting (whereby Per Ranstam is intended to be the auditor in charge).
Magnus Nylén holds a BA degree from Boston University and has extensive experience from national and international capital markets including The Royal Bank of Scotland, Alfred Berg Fondkommission, HSBC and Aros Fondkommission. Since 2013, Magnus Nylen is one of the owners of Partner Fondkommission, with offices in Göteborg and Stockholm.
SelectImmune Pharma develops novel immunotherapies against bacterial infections as alternatives or complements to antibiotics. Several of the company's drug candidates have shown protective effects against bacterial infections in animal models, including acute cystitis, severe kidney infection and urosepsis. One drug candidate, the Interleukin-1 receptor antagonist (IL1-RA) has successfully been used in the clinic and is currently being investigated in controlled Phase II trials to treat recurrent acute cystitis or bladder pain syndrome.
" We look forward to sharing Magnus Nylén's vast experience of the financial markets in Sweden and internationally," says Catharina Svanborg, Founder of SelectImmune Pharma.